Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX – Free Report) – Analysts at Brookline Capital Management cut their FY2026 earnings per share (EPS) estimates for Radiopharm Theranostics in a research note issued on Monday, December 15th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings of ($2.30) per share for the year, down from their prior forecast of ($2.25). Brookline Capital Management also issued estimates for Radiopharm Theranostics’ FY2027 earnings at ($2.43) EPS.
Other analysts also recently issued reports about the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Wednesday, October 8th. B. Riley reiterated a “buy” rating and issued a $16.00 target price (up from $13.00) on shares of Radiopharm Theranostics in a report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Radiopharm Theranostics has an average rating of “Buy” and a consensus target price of $15.33.
Radiopharm Theranostics Trading Down 10.9%
NASDAQ RADX opened at $5.34 on Thursday. Radiopharm Theranostics has a 12 month low of $3.50 and a 12 month high of $16.25. The stock has a 50-day simple moving average of $5.26 and a 200 day simple moving average of $5.24.
Institutional Trading of Radiopharm Theranostics
An institutional investor recently raised its position in Radiopharm Theranostics stock. PNC Financial Services Group Inc. raised its stake in Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX – Free Report) by 100.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 16,000 shares of the company’s stock after buying an additional 8,000 shares during the quarter. PNC Financial Services Group Inc. owned about 0.20% of Radiopharm Theranostics worth $88,000 at the end of the most recent reporting period.
About Radiopharm Theranostics
Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.
See Also
- Five stocks we like better than Radiopharm Theranostics
- Insider Trades May Not Tell You What You Think
- Cannabis Stocks Up for Reversal: Pipedreams or Opportunity?
- Comparing and Trading High PE Ratio Stocks
- Rate Cuts Make These 3 Income ETFs More Attractive Than Ever
- Why Are These Companies Considered Blue Chips?
- Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport
Receive News & Ratings for Radiopharm Theranostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radiopharm Theranostics and related companies with MarketBeat.com's FREE daily email newsletter.
